Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors

被引：20

作者：

Chatal, Jean-Francois ^{[1
]}

Davodeau, Francois ^{[1
]}

Cherel, Michel ^{[1
]}

Barbet, Jacques ^{[1
]}

机构：

[1] Univ Nantes, Dept Canc Res, INSERM, U601, Nantes, France

来源：

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS | 2009年 / 5卷

关键词：

Radioimmunotherapy; pretargeted radioimmunotherapy; alpha-immunotherapy; PHASE-II; ANTIBODY; RADIOSENSITIZATION; CARCINOMA; SYNERGY; HAPTEN; TRIAL;

D O I：

10.4103/0973-1482.55139

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Radioimmunotherapy (RIT) has been proven effective in the treatment of radiosensitive non-Hodgkin lymphoma but, for radioresistant solid tumors, new approaches are necessary to improve the clinical effectiveness. A real improvement has been the introduction of the pretargeting technology which appeared to be able to significantly increase tumor-to-normal organ uptake ratios.Another very promising approach consists in associating RIT with other treatment modalities. Finally the use of alpha particle-emitting radionuclides such as astatin-211 or bismuth-213 (alpha-RIT) should allow to efficiently eradicate disseminated microscopic clusters of tumor cells or isolated tumor cells which fit well with the short path length of alpha particles.

引用

页码：36 / 40

页数：5

共 21 条

[1]

Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma [J].

Barbet, J ;

Campion, L ;

Kraeber-Bodéré, F ;

Chatal, JF .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (11) :6077-6084

[2]

Bardies M, 1996, J NUCL MED, V37, P1853

[3]

Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy:: A collaborative study with the French Endocrine Tumor Group [J].

Chatal, JF ;

Campion, L ;

Kraeber-Bodéré, F ;

Bardet, S ;

Vuillez, JP ;

Charbonnel, B ;

Rohmer, V ;

Chang, CH ;

Sharkey, RM ;

Goldenberg, DM ;

Barbet, J .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (11) :1705-1711

[4]

Chérel M, 2006, Q J NUCL MED MOL IM, V50, P322

[5]

Couturier O, 1999, CLIN CANCER RES, V5, p3165S

[6]

Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts [J].

DeNardo, SJ ;

Kukis, DL ;

Kroger, LA ;

ODonnell, RT ;

Lamborn, KR ;

Miers, LA ;

DeNardo, DG ;

Meares, CF ;

DeNardo, GL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) :4000-4004

[7]

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma [J].

Forero, A ;

Weiden, PL ;

Vose, JM ;

Knox, SJ ;

LoBuglio, AF ;

Hankins, J ;

Goris, ML ;

Picozzi, VJ ;

Axworthy, DB ;

Breitz, HB ;

Sims, RB ;

Ghalie, RG ;

Shen, S ;

Meredith, RF .

BLOOD, 2004, 104 (01) :227-236

[8]

Combined 90yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft [J].

Gold, DV ;

Modrak, DE ;

Schutsky, K ;

Cardillo, TM .

INTERNATIONAL JOURNAL OF CANCER, 2004, 109 (04) :618-626

[9]

Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy [J].

Goldenberg, DM ;

Sharkey, RM ;

Paganelli, G ;

Barbet, J ;

Chatal, JF .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (05) :823-834

[10]

Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study [J].

Grana, C ;

Chinol, M ;

Robertson, C ;

Mazzetta, C ;

Bartolomei, M ;

De Cicco, C ;

Fiorenza, M ;

Gatti, M ;

Caliceti, P ;

Paganelli, G .

BRITISH JOURNAL OF CANCER, 2002, 86 (02) :207-212

← 1 2 3 →